News

2017

3/29/2017

ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer

1/20/2017

ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium

2016

12/29/2016

ARMO in the News Novel Interleukin-Based Immunotherapy Under Study in Pancreatic Cancer. OncLive. Go to Link

12/22/2016

ARMO BioSciences’ Immunotherapy AM0010 Receives Orphan Designation in Europe for the Treatment of Pancreatic Cancer

11/14/2016

ARMO BioSciences’ Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer

8/26/2016

ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

8/15/2016

ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology (JCO)

6/6/2016

ARMO BioSciences’ AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers

4/20/2016

ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016

4/18/2016

ARMO BioSciences Expands Leadership Team with the Appointment of Gail L. Brown, M.D. as Chief Medical Officer

3/28/2016

ARMO BioSciences to Present at the Jefferies Immuno-Oncology Summit

3/16/2016

ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences

2/24/2016

ARMO BioSciences to Present at Cowen and Company 36th Annual Heath Care Conference

2/10/2016

ARMO BioSciences Raises $50 Million Series C Financing

2/3/2016

ARMO BioSciences to Present at the Leerink Partners Global Healthcare Conference

1/8/2016

ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference